IntroductionDuring a comprehensive presentation by Dr. Catherine Coombs at UC Irvine, insights into the unique challenges and opportunities of using…
Browsing: Chronic Lymphocytic Leukemia
IntroductionDuring the recent CAR-T & Bispecifics conference, Dr. Nitin Jain, MD, from MD Anderson Cancer Center in Houston, Texas, presented…
David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member of the Rocky Mountain Cancer’s…
Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center, also serving as the Medical…
By: Christopher Flowers, MD Date: 09/22/2023 Dr. Christopher Flowers of MD Anderson Cancer Center expressed his gratitude to Sandeep for…
Chronic Lymphocytic Leukemia (CLL), a type of cancer that begins in the bone marrow and invades the blood, is one…
Barbara Eichhorst, MD Professor of Medicine at UNIVERSITÄTSKLINIKUM KÖLN, is the author of this OncologyTube.com video. Timestamps: 0:09 Can you…
Chronic Lymphocytic Leukemia (CLL) is a serious condition, and the current standard treatment involves a combination of Ibrutinib and Obinutuzumab…
Dr. Brian Hill, MD, PhD, from the Cleveland Clinic presented a study conducted through the Alliance and US cooperative groups,…
Acalabrutinib (AVO): A Promising New Triplet Treatment Option for High-Risk CLL Patients Phase 2 Study Results Matthew Davids By Matthew…
Zanubrutinib Outperforms Ibrutinib in Treating Relapsed/Refractory CLL/SLL Mehrdad Mobasher MD By Mehrdad Mobasher, MD, MPH The ALPINE study was a…
Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia By Elizabeth Brém, MD from UCI Health We focused basically on two…
Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia So I’m gonna start with chronic lymphocytic leukemia. And as part of…
Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment…
CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How…
CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How…
iFrame is not supported! Nemtabrutinib: Jennifer Woyach, MD ASH 2022 – BELLWAVE-001 Study By Jennifer Woyach, MD What did the…
Nemtabrutinib: Jennifer Woyach, MD ASH 2022 – BELLWAVE-001 Study By Jennifer Woyach, MD What did the BELLWAVE-01 study on Nemtabrutinib…
Zanubrutinib: Superior PFS in CLL Jennifer Brown, MD – ASH 2022 By Jennifer Brown, MD I’ll be discussing the alpine…
Calquence Tablet FDA Approved CLL, SLL, MCL Can You Tell Us The Significance Of The FDA’s Approval Of Calquence? The…
Professor Peter Hillmen, MD, he leads the Experimental Haematology section in LICAP and the Translational Haematology Research group. He is…
So, I presented the interim analysis of the second part of the FLARE trial, which is a randomized phase 3…
Priyanka A. Pophali, MD, Assistant Professor, Division of Hematology at the University of Wisconsin-Madison. In this video, she speaks about…
Priyanka A. Pophali, MD, Assistant Professor, Division of Hematology at the University of Wisconsin-Madison. In this video, she speaks about…
Lindsey E. Roeker, MD Hematologist Oncologist from Memorial Sloan Kettering Cancer Center speaks about the ASH 2021 Abstract – A…
Lindsey E. Roeker, MD Hematologist Oncologist from Memorial Sloan Kettering Cancer Center speaks about the ASH 2021 Abstract – A…
Paolo Ghia earned his medical degree from the University of Torino and then completed an internal medicine residency. He earned…
Paolo Ghia received his MD from the University of Torino, Italy, and received his PhD working at the Basel Institute…
Paul M. Barr, MD from the University of Rochester Medical Center Department of Neurobiology and Anatomy speaks about the ASCO…
John Pagel, MD from the Swedish Cancer Institute & CLL Society Inc. discusses the ASH 2020 Abstract – 127 Clonal…
Anthony Mato, MD of Memorial Sloan Kettering Cancer Center discusses ASH 2020 abstract – Oral presentation looking at real-world data…
John N. Allan, MD – Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell…
For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director…
Paolo Ghia, MD, Ph.D. of Università Vita-Salute San Raffaele speaks about ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib…
John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal…
John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal…
John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal…
Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD…
Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD…
Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD…
Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab forpreviously untreated patients with CLL: follow-up of efficacy and safety…
Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and…
Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab for previously untreated patients with CLL: follow-up of efficacy and…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Steven E.…
Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and…
Earn CME: https://www.naccme.com/program/19-lm-09 In this webcast from the ‘Understanding Waldenström’s Macroglobulinemia: A Guide to Diagnosis, Risk Stratification, and Current and…
John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed…
 VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, tells us about the results of…
Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impressions of the Phase 2 CAPTIVATE study investigating…
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates…
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, considers…
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, offers…
John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, considers whether minimal…
John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, tells us about…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA offers opinion on how physicians should be thinking…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers whether minimal residual disease (MRD) is a…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA tells us about the four-year update on the…
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, discusses how physicians should be thinking about the use of BTK…
John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses the…
John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers outlines the…
John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses how…
– If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with…
Robert Kreitman, MD of National Cancer Institute discusses Lumoxiti® phase III trial in patients with relapsed or refractory hairy cell…
Tanya Siddiqi, MD of @cityofhope discusses the updated results from transcend CLL 004, a Phase 1/2 study including patients with…
Jeff Sharman, MD of @TheUSONetwork discusses the phase III ELEVATE TN trial. _______ Read here:Â https://www.oncologytube.com/video/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukemia?channelName=Cancer-News
Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of…
Mohamed Zaki, MD of @abbvie discusses the phase 3 MURANO trial. ________ Read here:Â https://www.oncologytube.com/video/new-long-term-data-continues-to-demonstrate-progression-free-survival-and-overall-survival-benefits-with-venclexta-venclyxto-venetoclax-combination-in-patients-with-relapsed-refractory-ch-1
Jennifer Crombie, MD of @DanaFarber discusses a phase I study of duvelisib and venetoclax in patients with relapsed or refractory…
John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed…
Thanos Zomas, MD of @TakedaOncology discusses brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): 4-year update of…
Con Tam, MD of @PeterMacCC discusses the phase 2 CAPTIVATE clinical trial in CLL.: how this will affect clinicians and…
Con Tam, MD of @PeterMacCC discusses the phase 2 CAPTIVATE clinical trial in CLL.
– Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death…
Marco Montillo, MD of @ospniguarda discusses the phase III DUO study. _________ https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-copiktratm-duvelisib-presentations-0 https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-copiktratm-duvelisib-presentations
ASH 2016 Page 3 Maintenance Therapy in Chronic Lymphocytic Leukemia
ASH 2016 Page 2 Update on New Chronic Lymphocytic Leukemia Drugs
ASH 2016 Page 1 Long Term Follow-up with Ibrutinib in CLL Patients
CLL, What is the significance of IGHV mutations and how are they assessed
Not Your Fathers CLL with Dr. John Pagel
CLL, Is there a role still for chemo AND who should get chemo
CLL, FCR vs BR Is One Better
Paul M. Barr MD, Associate Professor of Medicine at Wilmot Cancer Institute elaborates on the role of CAR-T cell therapy…
Paul M.Barr MD Associate Professor of Medicine at Wilmot Cancer Institute explains the results found of the RESONATE Trial that…
Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute discusses the data found in the recent CLL-14…
Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line…
Rod Humerickhouse discusses the importance of Minimal Residual Disease Negativity. Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration…
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great…
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great…
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great…
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Potential Side Effects From Venetoclax + Rituximab In…
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses MRD As A Surrogate Marker In CLL. At…
Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses…
Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses…
Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Outcomes Of The illUMINTATE Trial. At The 60th ASH Annual Meeting…
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Testing For Minimal Residual Disease In CLL. At…
Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, Discusses…
Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR. At The…
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Treating CLL Patients With Venetoclax And Rituximab. At…
Carol Moreno, MD, PhD Hematologist, University of Barcelona, discusses Outcomes From The iLLUMINATE Trial. At The 60th ASH Annual Meeting…
Jeff Sharman, MD Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses…
Rod A. Humerickhouse, MD, PhD Group Project Leader, Oncology Development, AbbVie, discusses Recent Advancements In The Treatment Of CLL. At…
Carol Moreno, M.D., PhD Hematologist, University of Barcelona Discusses MRD As A Legitimate Surrogate Marker In CLL At The 60th…
Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology &…
Mitchell Smith, M.D., PhD Professor of Medicine and Associate Center Director for Clinical Investigations in the Division of Hematology &…
Kanti Rai, M.D. Professor of medicine at The Karches Center for Oncology Research, The Feinstein Institute for Medical Research; director…
Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses Acalabrutinib Monotherapy In CLL At The 60th ASH Annual…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Ongoing Trials For CLL Patients At The 60th ASH Annual Meeting…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Advances In New Cancer Regiments At The 60th ASH Annual Meeting…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Venetoclax & Carfilzomib Dose Escalation Study At The 60th ASH Annual…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Phase 3 MURANO Trial At The 60th ASH Annual Meeting on…
Rod Humerickhouse M.D., Asset Strategy Leader at ABBVIE discusses Benefits Of Venetoclax Studies At The 60th ASH Annual Meeting on…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an…
Neil E. Kay, M.D., Professor of Medicine at the Mayo Clinic College of Medicine and a Consultant in the Department…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Jacqueline Barrientos, M.D., Associate Professor, Division of Hematology and Medical Oncology, Department of Medicine, Donald and Barbara Zucker School of…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7314 In this presentation from the ‘Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application…
Earn CME: https://naccme.com/program/7308 In this Key Insights activity, Drs. Morton Coleman and Richard R. Furman discuss CLL-related highlights from Lymphoma…
Pierluigi Porcu, MD, from the Sidney Kimmel Cancer Center, Philadelphia, PA, discusses recent clinical developments that have provided healthcare professionals…
With new targets identified over the past few years, the development of precision medicine has expanded significantly. Speaking from the…
With cutaneous T-cell lymphoma (CTCL) being a rare disease with an incredibly high prevalence, Pierluigi Porcu, MD, from Sidney Kimmel…
At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu from Sidney Kimmel Cancer Center,…
Achieving measurable residual disease (MRD) negativity after completing therapy is an early indicator of overall survival. Presently, MRD testing is…
From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Barbara Eichhorst from the University Hospital Cologne, Cologne, Germany,…
Triple combination therapy is the administration of obinutuzumab, ibrutinib, and venetoclax in a sequential order. Barbara Eichhorst from the University…
Barbara Eichhorst from the University Hospital Cologne, Cologne, Germany, presents results from clinical trials testing an intensive fludarabine, cyclophosphamide, rituximab…
FCR chemoimmunotherapy is most effective in the IGVH mutated, non-17p deletion chronic lymphocytic leukemia (CLL) patient subgroup. With the advent…
While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the…
First line therapies for chronic lymphocytic leukemia (CLL) have developed beyond the historic approach of giving all patients FCR chemoimmunotherapy.…
Exciting updates on obinutuzumab were presented at the 23rd congress of the European Hematology Association (EHA) 2018, held in Stockholm,…
The MURANO study (NCT02005471) is a Phase III trial looking at rituximab in combination with either bendamustine or venetoclax for…
While the outcome for patients with chronic lymphocytic leukemia (CLL) has significantly improved over the last 30 years due to…
Achievement of a complete response and measurable residual disease (MRD) negativity are associated with improved survival in chronic lymphocytic leukemia…
In this video, Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, presents the first interim analysis of the…
Measurable residual disease (MRD) negativity is an important treatment endpoint for many hematological malignancies and has the potential to be…
In this video, Lydia Scarfò, MD, of Vita-Salute San Raffaele University, Milan, Italy, describes the studies on chronic lymphocytic leukemia…
Here, Lydia Scarfò, MD, of Vita-Salute San Raffaele University, Milan, Italy, gives an interesting insight about the possible reasons behind…
Patients with advanced chronic lymphocytic leukemia (CLL) don’t respond well to chimeric antigen receptor (CAR) T-cell therapy. In this interview,…
Chris Fegan, MB, MD, FRCP, FRCPath, from Cardiff University, Cardiff, UK, touches on several of the national and international cohort…
Telomere erosion and fusion play an important role in the pathology of many common human malignancies, including chronic lymphocytic leukemia…
To determine the true impact of ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL) within a population-based setting rather…
Venetoclax is making headlines due to its effectiveness against many hematological cancers. In this video, Giovanni Martinelli, MD, of the…
After presenting the initial results of a study investigating the efficacy of ibrutinib for chronic lymphocytic leukemia (CLL) within a…
Since its approval in late 2014, ibrutinib has primarily been studied in clinical trials, such as RESONATE (NCT01578707), and in…
Barbara Eichhorst, MD, from Uniklink Koln, Koln, Germany discusses the results of the recent Phase III CLL11 trial (NCT01998880). The…
Barbara Eichhorst, MD, from Uniklink Koln, Koln, Germany, talks to us about exciting new data for the venetoclax and rituximab…
Treating young patients with chronic lymphocytic leukemia (CLL) poses a unique set of challenges because treatment has to be effective…
Chronic lymphocytic leukemia (CLL) treatment is experiencing a shift away from chemotherapy in favor of novel agents. FCR chemotherapy, however,…
There has been a multitude of novel, exciting therapies within the field of chronic lymphocytic leukemia (CLL), explains Stephen Devereux,…
New genetic sequencing techniques could yield profound insights into disease progression in chronic lymphocytic leukemia (CLL). Niamh Appleby, MB, BAO,…
Speaking from the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Niamh Appleby, MB, BAO,…
The drive to find treatment options for chronic lymphocytic leukemia (CLL) with lower toxicities means clinicians are relying less and…
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, presented preliminary data from the Phase II CAPTIVATE trial (NCT02910583)…
Chronic lymphocytic leukemia (CLL) is usually fairly non-aggressive; however, there remain certain patients who have a rapidly progressing disease and…
The management of relapsed chronic lymphocytic leukemia (CLL) is a complex and difficult issue. We interviewed William Wierda, MD, PhD,…
Biomarker screening has become an essential component of constructing treatment plans in chronic lymphocytic leukemia (CLL). In this video, recorded…
Eliminating high toxicity, invasive treatments like chemotherapy and stem cell transplant is a goal of acute lymphoblastic leukemia (ALL) research.…
There has been an influx of novel agents in the field of chronic lymphocytic leukemia (CLL) in recent years. These…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, John Seymour, MBBS, FRACP,…
BCL-2 inhibitors like ibrutinib and venetoclax have been used in the treatment of lymphoproliferative disorders like chronic lymphocytic leukemia (CLL)…
MOR208 is an anti-CD19 monoclonal antibody that has been effective in treating a range of lymphomas, including diffuse large B-cell…
Measurable residual disease (MRD) is becoming increasingly important as a prognostic indicator in a wide variety of hematological malignancies. We…
The development of novel agents for treating chronic lymphocytic leukemia (CLL) has transformed the field in recent years. In this…
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, is the president of the European Research Initiative on…
The use of tyrosine kinase inhibitors (TKIs) in chronic lymphocytic leukemia (CLL) is expanding. In this video, recorded at the…
The CLL11 trial (NCT01998880) compared chlorambucil monotherapy with combination therapies of chlorambucil and anti-CD20 antibodies rituximab or obinutuzumab for chronic…
Novel agent combination therapies are coming to the forefront of chronic lymphocytic leukemia (CLL) research. Here, William Wierda, MD, PhD,…
MURANO (NCT02005471) is a Phase III randomized trial comparing the efficacy of venetoclax plus rituximab vs. standard chemoimmunotherapy of bendamustine…
Lymphoproliferative disorders can be characterized by a certain set of pathogenic events. These include the upregulation of anti-apoptotic pathways guided…
In chronic lymphocytic leukemia (CLL), treatment is often delayed because patients develop infections. Florence Cymbalista, PhD, from the Hôpital Avicenne,…
The CLARITY study (ISCRTN13751862) is the first clinical trial looking at the combination of venetoclax and ibrutinib for treating relapsed/refractory…
While the treatment landscape of chronic lymphocytic lymphoma (CLL) has been exciting with many breakthrough therapies, there are still key…
It is important that current techniques for the monitoring of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) are…
Minimal residual disease (MRD) is the small number of leukemic cells that remain after treatment and there are no signs…
In this whiteboard video, Dr. John N. Allan of Weill Cornell Medicine discusses the mechanisms of action of anti-apoptotic BCL2…
In this whiteboard video, Dr. John N. Allan of Weill Cornell Medicine discusses the mechanisms of action of anti-CD20 agents.…
In this whiteboard video, Dr. John N. Allan of Weill Cornell Medicine discusses the mechanisms of action of BRC signaling…
Robert Kreitman, MD, from the National Cancer Institute, Bethesda, MD, discusses a clinical trial using the recombinant immunotoxin, moxetumomab pasudotox,…
There are a growing number of investigations of novel combination therapies for chronic lymphocytic leukemia (CLL). These are discussed in…
The MURANO trial (NCT02005471) compared the benefit of venetoclax plus rituximab vs. bendamustine plus rituximab in chronic lymphocytic leukemia (CLL),…
Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from Leeds Teaching Hospital NHS Trust, Leeds, UK, provides an insight into the use…
In this interview, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from Leeds Teaching Hospital NHS Trust, Leeds, UK, details the importance…
The multitude of novel therapies in the field of chronic lymphocytic leukemia (CLL) paves the way for exciting future possibilities.…
Promising novel therapies are on the horizon within the field of chronic lymphocytic leukemia (CLL). Here, Jennifer Woyach, MD, of…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Anthony Mato, MD, MSCE, from…
Intolerance is the most common reason for discontinuing PI3K or BTK inhibitor drugs used for the treatment of chronic lymphocytic…
In this interview, Christopher Fox, MBChB(Hons), MRCP, FRCPath, of Nottingham University Hospitals NHS Trust, Nottingham, UK, provides an overview of…
Relapse and failure of ibrutinib and idelalisib regimens in chronic lymphocytic leukaemia (CLL) is becoming an increasingly common. Here, Christopher…
Current diagnostic techniques for chronic lymphocytic leukemia (CLL), which include Sanger sequencing and fluorescent in-situ hybridization, can be complex and…
Ana Limon Carrera, Takeda Oncology, talks about Working in Leukemias, Will Enter into Solid Tumors | Molecule TAK-931 is the…
Ana Limon Carrera, Takeda Oncology, talks about Studying Tumors in Pancreatic & Colorectal Patients | Hope to Confirm Safety &…
Michelle Dawson, MD, AstraZeneca, talks about Chemo-free Regimens for Patients Moxetumomab delivers different experience at Annual Meeting 2018.
Michelle Dawson, MD, AstraZeneca, talks AstraZeneca is Relatively New Six Agents in Phase 1 & another Six in Phase 2…
Rafael G Amado, MD, Adaptimmune, LLC, explains Updates of Positive CAR-T Studies & Approval Speaks to the power and potential…
Michelle Dawson, MD, AstraZeneca, talks about FDA Accepted Moxetumomab BLA Studies looking for toxicities and developments at Annual Meeting 2018.
Michelle Dawson, MD, AstraZeneca, talks about Adverse Effects for Moxetumomab Pasudotox Mild percentages of headache, nausea, HUS, CLS at Annual…
Michelle Dawson, MD, AstraZeneca, talks about Moxetumomab Pasudotox is Unique Immunotoxin Fused pseudomonas exotoxin with antibody variable at Annual Meeting…
Michelle Dawson, MD, AstraZeneca, talks about 75% Overall Response from Moxetumomab 41% of patients had complete response at Annual Meeting…
Michelle Dawson, MD, AstraZeneca, talks about Moxetumomab Pasudotox Pivotal in relapse refractory hairy cell leukemia at Annual Meeting 2018.
Paul G. Richardson, MD, explains Selinexor is a Novel Mechanism of Action Venetoclax Serves a Challenging Population at Imedex Great…
Paul G. Richardson, MD, explains Role of Venetoclax in Plasma Cell Leukemia Excellent partner drug with non-overlapping toxicities at Imedex…
Paul G. Richardson, MD, explains Powerful new IMiDs, CC-220 & CC-92480 Importance of Small Molecules in advanced trials at Imedex…
Paul G. Richardson, MD, explains Melflufen is a Modified Derivative of Melphalan Peptidase-avid and a targeted form of chemotherapy at…
Paul G. Richardson, MD, explains Selinexor is an Inhibitor of Nuclear Export Proteins Synergy with Bortezeomib on anti-myeloma activity at…
Paul G. Richardson, MD, explains Venetoclax Shown Great Results with Bortezomib It targets 11;14, oral, well-tolerated at Imedex Great Debates…
Richard R. Furman, MD, explains how Prognostics are difficult in the MBL population Del17P & NOTCH1 are relevant for time…
Amer M Zeidan, MBBS, explains Enasidenib, an IDH2 Inhibitor based on Phase 1 Trial High-Response rate in patients with IDH2…
Jose F. Leis, MD, PhD, explains the Treatment of CLL & Richter’s Transformations High Risk Patients will progress their disease…
Dramatic progress has been made in our understanding of the clinical, biological and molecular heterogeneity of chronic lymphocytic leukemia (CLL).…